The Editor's roundtable: Advances in stem cell therapy for treatment of cardiovascular disease

Vincent E. Friedewald, Joshua M. Hare, Leslie W. Miller, Howard T. Walpole, James T. Willerson, William C. Roberts

Research output: Contribution to journalComment/debatepeer-review

3 Scopus citations
Original languageEnglish (US)
Pages (from-to)807-816
Number of pages10
JournalAmerican Journal of Cardiology
Issue number6
StatePublished - Sep 15 2012
Externally publishedYes

Bibliographical note

Funding Information:
Dr. Hare: There is a very rapid proliferation of enthusiasm for this therapy among both the medical community and among patients. The medical community has a major responsibility to aggressively perform the appropriate studies that could lead to clinical approval of this therapy. Some forms of SC therapy have been approved in Europe. I predict that we will have approval in the United States for SC treatments sooner than most experts believe, perhaps within the next 3 to 5 years. One of the most important initiatives is the Cardiovascular Cell Therapy Research Network (CCTRN), funded by the National Institutes of Health. The CCTRN has devoted substantial resources to a multicenter network that Dr. Willerson, Dr. Miller, and I are honored to participate in. In this consortium, SC research trials can be conducted very quickly.

Funding Information:
This article is supported by a grant from the Okyanos Heart Institute, Freeport, The Bahamas.

Cite this